Translating into Русский. The English version is shown until it is ready.
HLB says FDA closed rivoceranib plant inspection as voluntary action indicated
Коротко
HLB said on Oct. 6 that the U.S. Food and Drug Administration classified a regular cGMP inspection of the finished-drug manufacturing facility for its liver cancer drug rivoceranib as voluntary action indicated (VAI). HLB's U.S. subsidiary Elevar Therapeutics received the inspection close-out letter from Chinese partner Hengrui Pharma on Oct. 3. The company said it is finalizing materials to resubmit a new drug application for the liver cancer treatment with Hengrui.
Читать полностью 2 мин чтения
HLB said on Oct. 6 that the U.S. Food and Drug Administration classified a regular cGMP inspection of the finished-drug manufacturing facility for rivoceranib, its liver cancer drug candidate, as voluntary action indicated (VAI). The company said its U.S. subsidiary Elevar Therapeutics received the inspection close-out letter from Chinese partner Hengrui Pharma on Oct. 3, confirming the inspection had been finalized under that category. Business outlets including Asia Economy, Korea Economic Daily and Newsis carried the announcement the same morning. [ 1 , 2 , 3 , 4 ]
Under the FDA's classification, VAI means inspections identified items requiring improvement that the company is judged able to correct on its own, so no separate administrative or regulatory action is recommended, according to the Seoul Economic Daily. The newspaper said the agency sorts facility inspection results into no action indicated (NAI), VAI and official action indicated (OAI), and that VAI is not in itself a product approval. [ 5 ]
The Seoul Economic Daily reported that rivoceranib is an oral targeted cancer drug that selectively inhibits VEGFR2 to block blood vessel formation toward tumor cells, and that Elevar is seeking first-line approval for hepatocellular carcinoma in combination with Hengrui's immunotherapy camrelizumab. The paper said the application received three complete response letters — in May 2024, March 2025 and July 2026 — with the most recent one caused by a problem at Hengrui's active pharmaceutical ingredient manufacturing facility. [ 5 ]
HLB has said it is working through the manufacturing-related items in sequence. The FDA closed its regular cGMP inspection of the rivoceranib active pharmaceutical ingredient facility as VAI in July, the Seoul Economic Daily reported, and the paper said the close-out letter at that time also stated that the VAI classification would not affect evaluation of a licensing application tied to the facility. With the finished-drug facility now also classified VAI, the newspaper said both facilities are out of the stage requiring formal regulatory action. [ 5 ]
HLB said Elevar and Hengrui are in the final stage of preparing materials needed for resubmission of the liver cancer new drug application and intend to file with the FDA as quickly as possible. An HLB official said the VAI classification was the result of Hengrui concentrating company-wide efforts to resolve the inspection findings, and that Elevar would cooperate closely with Hengrui to finish the resubmission preparations and respond without disruption to the FDA review that follows. [ 1 , 2 , 5 ]
Почему это важно
The VAI classification clears the finished-drug facility of the formal regulatory action category, removing a source of uncertainty that the Seoul Economic Daily tied to earlier rejections of the application. VAI is not itself an approval, so the timing of any U.S. launch still depends on the FDA's review after a resubmitted application, which the documents say has not yet been filed.
Ключевые факты
- The FDA classified the regular cGMP inspection of the rivoceranib finished-drug manufacturing facility as voluntary action indicated (VAI), HLB said. [ 1 , 2 , 4 , 5 ]
- HLB's U.S. subsidiary Elevar Therapeutics received the inspection close-out letter from partner Hengrui Pharma on Oct. 3. [ 1 , 2 , 5 ]
- VAI means FDA inspections found items requiring improvement that the company can correct on its own, without a separate formal regulatory action. [ 1 , 5 ]
- The FDA classifies inspection results as no action indicated (NAI), voluntary action indicated (VAI) or official action indicated (OAI), according to the Seoul Economic Daily. [ 5 ]
- Elevar and Hengrui are finalizing materials for resubmission of the liver cancer new drug application and plan to file with the FDA as soon as possible. [ 1 , 2 , 5 ]
- Rivoceranib is an oral targeted cancer drug that selectively inhibits VEGFR2, and Elevar is seeking first-line approval for hepatocellular carcinoma in combination with Hengrui's immunotherapy camrelizumab. [ 5 ]
- The application has received three complete response letters, in May 2024, March 2025 and July 2026, with the most recent one attributed to Hengrui's active pharmaceutical ingredient facility, according to the Seoul Economic Daily. [ 5 ]
Подтверждено несколькими источниками
- The FDA's regular cGMP inspection of the rivoceranib finished-drug manufacturing facility was classified as VAI. [ 1 , 2 , 4 , 5 ]
- Elevar received the inspection close-out letter from Hengrui on Oct. 3. [ 1 , 2 , 5 ]
- VAI indicates observations were found but that the company can correct them voluntarily, without official regulatory action being required. [ 1 , 5 ]
- Elevar and Hengrui are preparing to resubmit the liver cancer drug application to the FDA. [ 1 , 2 , 5 ]
Пока неясно
- When the NDA will actually be resubmitted to the FDA. The documents say only that Elevar plans to resubmit as soon as possible; no date is given.
- Whether the VAI classification will lead to approval of the liver cancer drug. The Seoul Economic Daily states that VAI itself does not mean product approval.
- Whether the July close-out letter for the active pharmaceutical ingredient facility said the VAI classification would not affect evaluation of a linked application. The Seoul Economic Daily attributes this to what was reported, and no other document confirms it.
- The location of the manufacturing facilities inspected by the FDA. The documents identify the facilities only as Hengrui's manufacturing sites.
Что пишут местные СМИ
Хронология, местное время
- Elevar Therapeutics receives the FDA inspection close-out letter for the rivoceranib finished-drug facility from Hengrui Pharma. [ 1 , 2 , 5 ]
- Asia Economy publishes a report on the VAI classification, citing an HLB statement issued that day. [ 1 ]
- Korea Economic Daily reports that the FDA inspection of the rivoceranib plant has wrapped up and NDA resubmission preparations are under way. [ 3 ]
- Newsis reports HLB's statement on the Hengrui inspection VAI classification. [ 4 ]
- Seoul Economic Daily reports on the facility inspection outcome and the drug's regulatory history. [ 5 ]
- The FDA closes its regular cGMP inspection of the rivoceranib active pharmaceutical ingredient facility as VAI, according to the Seoul Economic Daily. [ 5 ]